Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Stock Information for Aldeyra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aldeyra Therapeutics Inc.

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman
ALDX CLASS NOTICE: An Investigation has been Initiated on behalf of Aldeyra Therapeutics, Inc. Investors -- Contact BFA Law if You Lost Money (NASDAQ:ALDX)
ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law
ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. Securities Investigation Could Allow Investors to Recover Losses; Contact BFA Law (NASDAQ:ALDX)
ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations
ALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation; Contact BFA Law (NASDAQ:ALDX)
Kirby McInerney LLP Announces Investigation of Possible Claims Against Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
ALDX ALERT: BFA Law Informs Aldeyra Therapeutics, Inc. Investors to Contact the Firm about its Securities Investigation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.